TGFB1 and neoplasm: Delgoffe and coworkers found that oncolytic VACV-delivered TGFβ inhibitor could overcome the immunosuppressive tumor microenvironment by blocking the immunosuppressive function of TGF−β, and increasing the sensitivity to INF-γ (66).